ACE and COVID-19: In this randomized open-label trial of losartan versus usual care, our primary hypothesis was that losartan compared to usual care decreases 28-day mortality and is safe in adults not previously on ARBs or angiotensin-converting enzyme (ACE) inhibitors who were hospitalized for acute COVID-19.